QIMR Berghofer Medical Research Institute, Herston, Australia.
School of Biomedical Science, University of Queensland, Brisbane, Queensland, Australia.
Am J Respir Crit Care Med. 2020 Jun 1;201(11):1358-1371. doi: 10.1164/rccm.201906-1149OC.
: Respiratory syncytial virus (RSV) bronchiolitis causes significant infant mortality. Bronchiolitis is characterized by airway epithelial cell (AEC) death; however, the mode of death remains unknown.: To determine whether necroptosis contributes to RSV bronchiolitis pathogenesis via HMGB1 (high mobility group box 1) release.: Nasopharyngeal samples were collected from children presenting to the hospital with acute respiratory infection. Primary human AECs and neonatal mice were inoculated with RSV and murine , respectively. Necroptosis was determined via viability assays and immunohistochemistry for RIPK1 (receptor-interacting protein kinase-1), MLKL (mixed lineage kinase domain-like pseudokinase) protein, and caspase-3. Necroptosis was blocked using pharmacological inhibitors and RIPK1 kinase-dead knockin mice.: HMGB1 levels were elevated in nasopharyngeal samples of children with acute RSV infection. RSV-induced epithelial cell death was associated with increased phosphorylated RIPK1 and phosphorylated MLKL but not active caspase-3 expression. Inhibition of RIPK1 or MLKL attenuated RSV-induced HMGB1 translocation and release, and lowered viral load. MLKL inhibition increased active caspase-3 expression in a caspase-8/9-dependent manner. In susceptible mice, infection upregulated RIPK1 and MLKL expression in the airway epithelium at 8 to 10 days after infection, coinciding with AEC sloughing, HMGB1 release, and neutrophilic inflammation. Genetic or pharmacological inhibition of RIPK1 or MLKL attenuated these pathologies, lowered viral load, and prevented type 2 inflammation and airway remodeling. Necroptosis inhibition in early life ameliorated asthma progression induced by viral or allergen challenge in later life.: infection induces AEC necroptosis. Inhibition of necroptosis may be a viable strategy to limit the severity of viral bronchiolitis and break its nexus with asthma.
呼吸道合胞病毒(RSV)毛细支气管炎导致婴儿死亡率显著升高。毛细支气管炎的特征在于气道上皮细胞(AEC)死亡;然而,其死亡方式仍不清楚。本研究旨在通过高迁移率族蛋白 1(HMGB1)的释放,确定坏死性凋亡是否通过 HMGB1 释放促进 RSV 毛细支气管炎发病机制。从因急性呼吸道感染到医院就诊的儿童中收集鼻咽样本。用人 RSV 和鼠 RSV 分别接种原代人 AEC 和新生鼠。通过细胞活力测定和 RIPK1(受体相互作用蛋白激酶 1)、MLKL(混合谱系激酶结构域样伪激酶)蛋白和 caspase-3 的免疫组织化学来确定坏死性凋亡。使用药理学抑制剂和 RIPK1 激酶失活基因敲入小鼠阻断坏死性凋亡。在急性 RSV 感染儿童的鼻咽样本中,HMGB1 水平升高。RSV 诱导的上皮细胞死亡与磷酸化 RIPK1 和磷酸化 MLKL 的增加相关,但与活性 caspase-3 表达无关。抑制 RIPK1 或 MLKL 可减弱 RSV 诱导的 HMGB1 易位和释放,并降低病毒载量。MLKL 抑制以 caspase-8/9 依赖的方式增加活性 caspase-3 的表达。在易感小鼠中,感染后 8 至 10 天,气道上皮细胞中 RIPK1 和 MLKL 的表达上调,同时伴有 AEC 脱落、HMGB1 释放和中性粒细胞炎症。RIPK1 或 MLKL 的遗传或药理学抑制减轻了这些病理变化,降低了病毒载量,并防止了 2 型炎症和气道重塑。生命早期抑制坏死性凋亡可改善生命后期病毒或过敏原挑战引起的哮喘进展。本研究表明,感染诱导 AEC 坏死性凋亡。抑制坏死性凋亡可能是限制病毒毛细支气管炎严重程度并打破其与哮喘联系的可行策略。